

Approved on 20 December 2021

The Board:

1. Approves the revised budget recommended for the grant listed in Table 2 of GF/B46/ER09 ("Table 2");
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

**Table 2: Secretariat’s Recommendation on Additional Funding to be Integrated into Grants**

Please note that each country name is linked to the extranet site where supporting documents are available for review.

<b>N</b>	<b>Applicant</b>	<b>Disease Component</b>	<b>Grant Name</b>	<b>Additional Funding Source</b>	<b>Currency</b>	<b>Previous Approved Grant Budget</b>	<b>Additional Funds</b>	<b>Revised Grant Budget for approval</b>	<b>Rationale</b>
1	<a href="#">Bangladesh</a>	Malaria	BGD-M-NMCP	Private Sector: Comic Relief Inc.	US\$	21,275,213	1,529,985	22,805,198	This additional funding from Comic Relief Inc. will be invested in service delivery and in-country distribution activities.
2	<a href="#">Liberia</a>	Malaria	LBR-M-PII	Private Sector: Co-impact	US\$	18,146,967	1,901,845	20,048,812	The additional funding from Co-Impact will be invested in scaling up National Community Health Assistant Program in Montserrado. While there is an ongoing OIG investigation in Liberia, the Principal Recipient, Plan International, Inc., is not implicated in the investigation.